Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zimmer Biomet Holdings is conducting a clinical study titled ‘Clinical Investigation to Demonstrate Performance, Safety and Clinical Benefits of the Persona Revision Knee System.’ The study aims to evaluate the performance, safety, and clinical benefits of the Persona Revision Knee System in patients undergoing primary or revision total knee arthroplasty. This research is significant as it seeks to improve outcomes for patients with knee complications, infections, and osteoarthritis.
The intervention being tested is the Persona Revision Knee System, a device designed for use in both primary and revision knee surgeries. It aims to enhance the surgical outcomes and patient satisfaction by providing a reliable knee replacement solution.
The study is observational in design, utilizing a multicenter, single-arm, consecutive series, retrospective cohort model with prospective follow-up. This means the study observes outcomes in a group of patients who have already received the intervention, without random allocation or blinding.
The study began on March 23, 2021, with its primary completion and estimated study completion dates yet to be announced. The most recent update was submitted on October 22, 2025, indicating ongoing progress and data collection.
This clinical update could positively influence Zimmer Biomet’s stock performance and investor sentiment, as successful outcomes may enhance the company’s market position in the competitive orthopedic device industry. Investors should monitor this study’s progress for potential impacts on the market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.